Novo Nordisk obesity drug linked to rare cause of sight loss
The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
Bridging research and clinical guidelines – interactive stra...
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Deep Dive: Research and Development 2025
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
Life Sciences Industry Report - Biologics and Generics
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat...
At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
Life Sciences Industry Report - Oncology
Developments in the oncology space in 2024 brought hope to both industry and patients.
Axtria Ignite 2025: Leading in an Agentic Era
Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This
Operationalize: Expanded Access Programs comes to the West C...
Improving Global Access to Life-Changing Therapeutics...
